Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03454451
Title CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Corvus Pharmaceuticals, Inc.

renal cell carcinoma

triple-receptor negative breast cancer

urinary bladder cancer

colorectal cancer

uterine cancer


prostate cancer

cervical cancer

endometrial cancer

lung non-small cell carcinoma



CPI-006 + Pembrolizumab

CPI-006 + CPI-444

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.